Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [DOG and BVA guideline no. 24b : Noninfectious uveitis posterior].

Literature DB >> 29159575

[DOG and BVA guideline no. 24b : Noninfectious uveitis posterior].

Abstract

Entities: Disease Species

Mesh：

Year: 2017 PMID： 29159575 DOI： 10.1007/s00347-017-0582-z

Source DB: PubMed Journal: Ophthalmologe ISSN： 0941-293X Impact factor: 1.059

Keyword Cloud
References

× No keyword cloud information.

87 in total

Review 1. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

Authors: D A Jabs; J T Rosenbaum; C S Foster; G N Holland; G J Jaffe; J S Louie; R B Nussenblatt; E R Stiehm; H Tessler; R N Van Gelder; S M Whitcup; D Yocum
Journal: Am J Ophthalmol Date: 2000-10 Impact factor: 5.258

2. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease.

Authors: K Masuda; A Nakajima; A Urayama; K Nakae; M Kogure; G Inaba
Journal: Lancet Date: 1989-05-20 Impact factor: 79.321

3. Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.

Authors: John H Kempen; Michael M Altaweel; Lea T Drye; Janet T Holbrook; Douglas A Jabs; Elizabeth A Sugar; Jennifer E Thorne
Journal: Ophthalmology Date: 2015-08-20 Impact factor: 12.079

4. Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study.

Authors:
Journal: Ophthalmology Date: 2015-08-19 Impact factor: 12.079

5. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.

Authors: Grace Levy-Clarke; Douglas A Jabs; Russell W Read; James T Rosenbaum; Albert Vitale; Russell N Van Gelder
Journal: Ophthalmology Date: 2013-12-17 Impact factor: 12.079

Review 6. Understanding uveitis: the impact of research on visual outcomes.

Authors: Marc D de Smet; Simon R J Taylor; Bahram Bodaghi; Elisabetta Miserocchi; Philip I Murray; Uwe Pleyer; Manfred Zierhut; Talin Barisani-Asenbauer; Phuc LeHoang; Sue Lightman
Journal: Prog Retin Eye Res Date: 2011-07-22 Impact factor: 21.198

7. Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases.

Authors: Joshua D Udoetuk; Yang Dai; Gui-Shuang Ying; Ebenezer Daniel; Sapna Gangaputra; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; C Stephen Foster; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; John H Kempen
Journal: Ophthalmology Date: 2012-04-06 Impact factor: 12.079